Type 2 Diabetes

The screening of more than 50,000 youth patients in diverse populations of Colorado and Bavaria, Germany reported no association between infection and T1D.

Data from a 14-week randomized clinical trial suggests adherence to a time-restricted diet was associated with significant differences in weight loss and improvements in blood pressure compared to a typical diet.

Dr. Gregory Weiss provides perspective on a recent study examining associations between serum ceramide levels and the likelihood of achieving normoglycemia among patients who have undergone RYGB.

An analysis of more than 20 years of follow-up data from more than 4000 patients in the Malmö Diet and Cancer Study shed light on associations between prostasin concentrations and risk of developing diabetes and cancer mortality.

A retrospective study provides insight into the ability of CGM technology to improve glycemic control in in-hospital settings and, potentially, reduce the risk of spreading infectious diseases.

Our endocrinology month in review spotlights the most popular content from the past month. The top content from July includes hormone therapy guidance from NAMS, a comparison of management practices among Medicare beneficiaries, and a recap of the top approvals from the first half of 2022.

The highest adjusted probability of CGM use occurred in middle adulthood, while the probability of CGM utilization decreased with increasing age in older adulthood.

For the July 2022 episode of Diabetes Dialogue: Therapeutics, Technology, and Real-World Perspectives, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, sit down to provide perspective on the latest advances in the fight to cure type 1 diabetes and offer insight into their experiences at the Practical Ways to Achieve Targets in Diabetes Care Conference held in Keystone, CO in mid-July.

An analysis of the DCCT and EDIC studies provides clinicians with insights into the risk factors associated with incident cancer diagnoses among patients with type 1 diabetes, suggesting those using higher daily doses of insulin had a more than 4-fold increase in risk of a cancer diagnosis.

New data report a slightly higher but nonsignificant increase in diabetes incidence among children in Canada during COVID-19 pandemic.

The new recommendation acknowledges the role of disease-preventive behaviors that can be taken on by approximately 12% of the US population.

A randomized crossover trial assessing the effects of a 3-week time-restricted eating regimen details the impact of the approach on time in range and other glycemic measures among adults with type 2 diabetes.

Jennifer Green, MD, discusses the benefit of relatively new innovations including continuous glucose monitoring and smart insulin pens.

Data from a major trial detail the cardiorenal benefits of dapagliflozin use among patients with type 2 diabetes based on use of background cardiovascular medications.

Our latest case report from Brady Pregerson, MD, features a man in his 30s with a history of type 1 diabetes mellitus on insulin presenting to the emergency department for left index finger pain and swelling. Can you determine the correct diagnosis?

During follow-up, 2.6% of the patients were diagnosed with depression, while 32.1% were treated with antidepressants.

The Duke expert reviews key strategies for starting and continuing care with the pivotal glycemic control agent.

An analysis of data from more than 450,000 patients in the UK details an 81% increase in the net incidence of diabetes in the first 4 weeks after contracting COVID-19, which remained elevated through weeks 5-12, compared to those who did not contract COVID-19.

Data show metformin was associated with reduced odds of developing AMD, with low to moderate doses having the greatest potential benefit.

An analysis comparing prescribing practices for Medicare Advantage beneficiaries against those in fee-for-service programs suggests Advantage patients were more likely to receive ACE inhibitors or ARBs, but 20% less likely to receive GLP-1 RAs and 9% less likely to receive SGLT2 inhibitors.

An analysis from investigators in Sweden suggests patients with acromegaly with diabetes had a 58% greater risk of overall mortality and a more than 2-fold increase in risk of cardiovascular mortality compared to their counterparts without diabetes.

The Optimal screening ages for two measurements were 2 years and 6 years for the diagnosis of clinical type 1 diabetes.

There was no association found between ever using metformin and the risk of either IBD, Crohn’s disease, or ulcerative colitis.

An analysis of nationally representative data from NHANES cycles from 1999-2000 through 2017-2018 suggests just 6.8% of US adults had optimal cardiometabolic health.

New data from a study performed by investigators at UVA Health details the accuracy of blood glucose measurements with factory-calibrated CGMs in patients undergoing dialysis.